Management of Hypertension with Persistent Albuminuria in a Prediabetic Patient

Immediate Medication Adjustments

The European Society of Cardiology recommends increasing valsartan to 320 mg daily to maximize albuminuria reduction, and maintaining amlodipine 5 mg as part of the combination, which is guideline-concordant (RAS blocker + calcium channel blocker) 1, 2
Target systolic BP to 130 mmHg and <130 mmHg if tolerated, but not <120 mmHg, as recommended by the European Society of Cardiology 1, 2
Target diastolic BP <80 mmHg but not <70 mmHg, according to the European Society of Cardiology 1

The European Society of Cardiology recommends adding empagliflozin, canagliflozin, or dapagliflozin to reduce CV events and slow CKD progression in patients with prediabetes/diabetes at very high cardiovascular risk 1, 4
SGLT2 inhibitors provide dual benefit: they lower albuminuria and reduce cardiovascular mortality independent of glucose-lowering effects, as stated by the European Society of Cardiology 1

The American Heart Association recommends smoking cessation as mandatory and non-negotiable, as smoking dramatically accelerates both cardiovascular disease and diabetic kidney disease progression 3, 5, 6
Implement DASH-style eating pattern with sodium restriction to <2,300 mg/day, as recommended by the American Diabetes Association 7

The European Society of Cardiology recommends initiating high-intensity statin therapy targeting LDL-C <55 mg/dL (1.4 mmol/L) with ≥50% reduction from baseline 1, 6

The American Diabetes Association recommends targeting HbA1c <7.0% (53 mmol/mol) to prevent microvascular complications 1, 8

The European Society of Cardiology recommends monitoring serum creatinine/eGFR and potassium at baseline, then at least annually, and checking urine albumin-to-creatinine ratio every 3-6 months to assess treatment response 1, 7
Office BP should be checked monthly until target achieved, then every 3 months, as recommended by the European Society of Cardiology 2

The European Society of Cardiology recommends never combining valsartan with an ACE inhibitor or direct renin inhibitor due to increased risk of hyperkalemia, syncope, and acute kidney injury without added cardiovascular benefit 1, 7
Do not delay SGLT2 inhibitor initiation until frank diabetes develops—the benefit is greatest when started early in patients with albuminuria, as stated by the European Society of Cardiology 1, 4

SGLT2 inhibitor addition reduces risk of renal endpoints and cardiovascular events by approximately 30-40%, according to the European Society of Cardiology 1